|
1
|
Prat A, Adamo B, Cheang MC, Anders CK,
Carey LA and Perou CM: Molecular characterization of basal-like and
non-basal-like triple-negative breast cancer. Oncologist.
18:123–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nassar A, Sussman ZM, Lawson D and Cohen
C: Inference of the Basal epithelial phenotype in breast carcinoma
from differential marker expression, using tissue microarrays in
triple negative breast cancer and women younger than 35. Breast J.
18:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choi WT, Yang Y, Xu Y and An J: Targeting
chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor
progression and metastasis. Curr Top Med Chem. 14:1574–1589. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jin F, Brockmeier U, Otterbach F and
Metzen E: New insight into the SDF-1/CXCR4 axis in a breast
carcinoma model: Hypoxia-induced endothelial SDF-1 and tumor cell
CXCR4 are required for tumor cell intravasation. Mol Cancer Res.
10:1021–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luker KE, Lewin SA, Mihalko LA, Schmidt
BT, Winkler JS, Coggins NL, Thomas DG and Luker GD: Scavenging of
CXCL12 by CXCR7 promotes tumor growth and metastasis of
CXCR4-positive breast cancer cells. Oncogene. 31:4750–4758. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chu QD, Panu L, Holm NT, Li BD, Johnson LW
and Zhang S: High chemokine receptor CXCR4 level in triple negative
breast cancer specimens predicts poor clinical outcome. J Surg Res.
159:689–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petersen ER, Sørensen PD, Jakobsen EH,
Madsen JS and Brandslund I: Serum HER-2 predicts response and
resistance to trastuzumab treatment in breast cancer. Clin Chem Lab
Med. 51:1483–1492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F,
Wang D, Chen W, Huang O, Chen X, et al: Overexpression of
epithelial growth factor receptor (EGFR) predicts better response
to neo-adjuvant chemotherapy in patients with triple-negative
breast cancer. J Transl Med. 10:(Suppl 1). S42012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Skedgel C, Rayson D and Younis T: Is
adjuvant trastuzumab a cost-effective therapy for
HER-2/neu-positive T1bN0 breast cancer? Ann Oncol. 24:1834–1840.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burness ML, Grushko TA and Olopade OI:
Epidermal growth factor receptor in triple-negative and basal-like
breast cancer: Promising clinical target or only a marker? Cancer
J. 16:23–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brand TM, lida M, Luthar N, Starr MM,
Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in
cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Masuda H, Zhang D, Bartholomeusz C,
Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth
factor receptor in breast cancer. Breast Cancer Res Treat.
136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahimi M, George J and Tang C: EGFR
variant-mediated invasion by enhanced CXCR4 expression through
transcriptional and post-translational mechanisms. Int J Cancer.
126:1850–1860. 2010.PubMed/NCBI
|
|
14
|
Salvucci O, Bouchard A, Baccarelli A,
Deschênes J, Sauter G, Simon R, Bianchi R and Basik M: The role of
CXCR4 receptor expression in breast cancer: A large tissue
microarray study. Breast Cancer Res Treat. 97:275–283. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cabioglu N, Summy J, Miller C, Parikh NU,
Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE:
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu
in breast cancer cells by a novel pathway involving Src kinase
activation. Cancer Res. 65:6493–6497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Phillips RJ, Mestas J, Gharaee-Kermani M,
Burdick MD, Sica A, Belperio JA, Keane MP and Strieter RM:
Epidermal growth factor and hypoxia-induced expression of CXC
chemokine receptor 4 on non-small cell lung cancer cells is
regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian
target of rapamycin signaling pathway and activation of hypoxia
inducible factor-1alpha. J Biol Chem. 280:22473–22481. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahimi M, Toth TA and Tang CK: CXCR4
suppression attenuates EGFRvIII-mediated invasion and induces p38
MAPK-dependent protein trafficking and degradation of EGFRvIII in
breast cancer cells. Cancer Lett. 306:43–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T,
Wang J, Li J, Du Q and Sun B: Correlation effect of EGFR and CXCR4
and CCR7 chemokine receptors in predicting breast cancer metastasis
and prognosis. J Exp Clin Cancer Res. 29:162010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin Z, Zhao C, Han X and Han Y: Wnt5a
promotes ewing sarcoma cell migration through upregulating CXCR4
expression. BMC Cancer. 12:4802012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu J, Zhang B, Wu M, Li H, Niu R, Ying G
and Zhang N: Screening of a PKC zeta-specific kinase inhibitor
PKCzI257.3 which inhibits EGF-induced breast cancer cell
chemotaxis. Invest New Drugs. 28:268–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lapteva N, Yang AG, Sanders DE, Strube RW
and Chen SY: CXCR4 knockdown by small interfering RNA abrogates
breast tumor growth in vivo. Cancer Gene Ther. 12:84–89. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spina A, Di Maiolo F, Esposito A, Sapio L,
Chiosi E, Sorvillo L and Naviglio S: cAMP elevation down-regulates
β3 integrin and focal adhesion kinase and inhibits leptin-induced
migration of MDA-MB-231 breast cancer cells. Biores Open Access.
1:324–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ye Q, Kantonen S and Gomez-Cambronero J:
Serum deprivation confers the MDA-MB-231 breast cancer line with an
EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. J Mol
Biol. 425:755–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murillo G, Peng X, Torres KE and Mehta RG:
Deguelin inhibits growth of breast cancer cells by modulating the
expression of key members of the Wnt signaling pathway. Cancer Prev
Res (Phila). 2:942–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pattarozzi A, Gatti M, Barbieri F, Würth
R, Porcile C, Lunardi G, Ratto A, Favoni R, Bajetto A, Ferrari A
and Florio T: 17beta-estradiol promotes breast cancer cell
proliferation-inducing stromal cell-derived factor-1-mediated
epidermal growth factor receptor transactivation: Reversal by
gefitinib pretreatment. Mol Pharmacol. 73:191–202. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sales KJ, Grant V, Catalano RD and Jabbour
HN: Chorionic gonadotrophin regulates CXCR4 expression in human
endometrium via E-series prostanoid receptor 2 signalling to
PI3K-ERK1/2: Implications for fetal-maternal crosstalk for embryo
implantation. Mol Hum Reprod. 17:22–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang YJ, Wang QY, Zhou CX, Yin QQ, He M,
Yu XT, Cao DX, Chen GQ, He JR and Zhao Q: MiR-124 targets Slug to
regulate epithelial-mesenchymal transition and metastasis of breast
cancer. Carcinogenesis. 34:713–722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hallett MA, Teng B, Hasegawa H, Schwab LP,
Seagroves TN and Pourmotabbed T: Anti-matrix metalloproteinase-9
DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of
breast cancer. Breast Cancer Res. 15:R122013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nasser MW, Qamri Z, Deol YS, Smith D,
Shilo K, Zou X and Ganju RK: Crosstalk between chemokine receptor
CXCR4 and cannabinoid receptor CB2 in modulating breast cancer
growth and invasion. PLoS One. 6:e239012011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liedtke C, Hess KR, Karn T, Rody A, Kiesel
L, Hortobagyi GN, Pusztai L and Gonzalez-Angulo AM: The prognostic
impact of age in patients with triple-negative breast cancer.
Breast Cancer Res Treat. 138:591–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wendel C, Hemping-Bovenkerk A, Krasnyanska
J, Mees ST, Kochetkova M, Stoeppeler S and Haier J: CXCR4/CXCL12
participate in extravasation of metastasizing breast cancer cells
within the liver in a rat model. PLoS One. 7:e300462012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee MF, Pan MH, Chiou YS, Cheng AC and
Huang H: Resveratrol modulates MED28 (Magicin/EG-1) expression and
inhibits epidermal growth factor (EGF)-induced migration in
MDA-MB-231 human breast cancer cells. J Agric Food Chem.
59:11853–11861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thike AA, Cheok PY, Jara-Lazaro AR, Tan B,
Tan P and Tan PH: Triple-negative breast cancer:
Clinicopathological characteristics and relationship with
basal-like breast cancer. Mod Pathol. 23:123–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY,
Cho DH, Kim S, Choe JH, Lee JE, Kim JH, et al: The prognoses of
metaplastic breast cancer patients compared to those of
triple-negative breast cancer patients. Breast Cancer Res Treat.
126:471–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi YL, Oh E, Park S, Kim Y, Park YH,
Song K, Cho EY, Hong YC, Choi JS, Lee JE, et al: Triple-negative,
basal-like, and quintuple-negative breast cancers: Better
prediction model for survival. BMC Cancer. 10:5072010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chacón RD and Costanzo MV: Triple-negative
breast cancer. Breast Cancer Res. 12:(Suppl 2). S32010. View Article : Google Scholar
|
|
38
|
Boudot A, Kerdivel G, Habauzit D,
Eeckhoute J, Le Dily F, Flouriot G, Samson M and Pakdel F:
Differential estrogen-regulation of CXCL12 chemokine receptors,
CXCR4 and CXCR7, contributes to the growth effect of estrogens in
breast cancer cells. PLoS One. 6:e208982011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hawkins OE and Richmond A: The dynamic
yin-yang interaction of CXCR4 and CXCR7 in breast cancer
metastasis. Breast Cancer Res. 14:1032012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lill NL and Sever NI: Where EGF receptors
transmit their signals. Sci Signal. 5:pe412012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsai PC, Hsieh CY, Chiu CC, Wang CK, Chang
LS and Lin SR: Cardiotoxin III suppresses MDA-MB-231 cell
metastasis through the inhibition of EGF/EGFR-mediated signaling
pathway. Toxicon. 60:734–743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu D, He J, Yuan Z, Wang S, Peng R, Shi
Y, Teng X and Qin T: EGFR expression correlates with decreased
disease-free survival in triple-negative breast cancer: A
retrospective analysis based on a tissue microarray. Med Oncol.
29:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Billadeau DD, Chatterjee S, Bramati P,
Sreekumar R, Shah V, Hedin K and Urrutia R: Characterization of the
CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest
Cancer. 37:110–119. 2006.PubMed/NCBI
|
|
44
|
Yasumoto K, Yamada T, Kawashima A, Wang W,
Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K and
Yano S: The EGFR ligands amphiregulin and heparin-binding egf-like
growth factor promote peritoneal carcinomatosis in CXCR4-expressing
gastric cancer. Clin Cancer Res. 17:3619–3630. 2011. View Article : Google Scholar : PubMed/NCBI
|
